Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) Announces Upcoming Investor Conference Presentations

BOTHELL, WA--(Marketwire - July 29, 2010) - Marina Biotech, Inc. (NASDAQ: MRNAD), formerly known as MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that J. Michael French, Marina’s President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at the following upcoming conferences:

• The BMO Capital Markets 10^th Annual Focus on Healthcare Conference, on Thursday, August 5 at 4:00 p.m. Eastern Time at the Sheraton New York Hotel and Towers in New York City, New York; and

• The CANACCORD/Genuity 30^th Annual Global Growth Conference 2010, on Wednesday, August 11 at 9:30 a.m. Eastern Time at the InterContinental Hotel in Boston, Massachusetts.

A live audio webcast of each presentation will be available on the Event Calendar pages of the Investors section of the Company’s website at http://www.marinabio.com. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation and will be archived for three months.

About Marina Biotech, Inc.

Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Marina’s pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina’s goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.